Autologous Peripheral Blood Mononuclear Cell Recognition of Autologous Proliferating Tumor Cells in the Context of a Patient-Specific Vaccine Trial
Table 2
Comparison of patient characteristics in the two cohorts with ELISPOT results less than or greater than 5 spots/100 K PBMC in response to autologous tumor cells at week 0 and week 4 after receiving dendritic-cell-based antimelanoma therapy.
All
Week 0 (<5 spots)
Week 0 (>5 spots)
Week 4 (<5 spots)
Week 4 (>5 spots)
Sex
M
26
14
12
15
11
F
16
8
8
7
9
Age (years)
49.3 ± 14.1
46.0 ± 14.8
52.9 ± 12.8
46.7 ± 14.3
52.0 ± 13.8
Disease status
M1a/b
20
7
13
7
13
M1c
22
15
7
15
7
Anergy
11
6
5
6
5
Prior treatment
RT
6
3
3
3
3
Chemo
12
6
6
5
7
IL-2
10
7
3
6
4
IFN-alpha
15
9
6
8
7
GM-CSF
18
9
9
9
9
Vaccine
6
3
3
3
3
BCG
2
1
1
0
2
mAb
1
1
0
1
0
Biochemo
16
11
5
11
5
DC phenotype
% CD80
38.6 ± 15.1
33.5 ± 15.2
44.4 ± 13.1
34.9 ± 14.7
42.8 ± 14.8
% CD83
10.9 ± 7.4
12.2 ± 7.0
9.5 ± 7.7
12.5 ± 7.1
9.1 ± 7.5
% CD86
82.5 ± 9.3
78.1 ± 13.5
69.6 ± 19.6
77.3 ± 13.0
70.4 ± 20.3
% CD11c
90.6 ± 7.3
89.3 ± 7.9
92.0 ± 6.4
88.8 ± 7.7
92.7 ± 6.3
Doses 1–3
Cell no. × 106
16.3 ± 7.0
16.2 ± 6.8
16.4 ± 7.2
16.1 ± 7.2
16.4 ± 6.7
% Viability
80.4 ± 9.6
79.0 ± 9.6
82.0 ± 9.1
81.0 ± 9.6
79.8 ± 9.8
DTH
DTH+ (week 0)
0
0
0
0
0
DTH+ (week 4)
4 (2 eqv)
2 (2 eqv)
2
1 (1 eqv)
3
ECOG status
0
30
18
12
18
12
1
10
3
7
3
7
2
2
1
1
1
1
serum LDH (ng/mL)
LDH (week 0)
578.6 ± 391.3
453.2 ± 93.7
716.6* ± 531.4
487.6 ± 162.3
678.7 ± 530.2
LDH (week 4)
594.6 ± 504.9
441.7 ± 92.9
762.9* ± 695.5
496.1 ± 321.6
703.1* ± 642.0
Each value is average ± SD where applicable. M1a: distant skin, lymph nodes, M1b: lung, and M1c: brain, liver or other visceral organs. RT: radiotherapy, Chemo: chemotherapy (temodar, cisplatin, vinblasin, tamoxifen, etc.), Vaccine: allogeneic tumor cell/lysate or peptide vaccines, BCG: bacillus calmette guerin, mAb: MDX-010, Biochemo: IL-2 ± IFN plus chemotherapy, DTH: delayed type hypersensitivity, eqv: equivocal result, LDH: lactose dehydrogenase. compared to <5 spots/100 K PBMC.
